Topics of discussion:
Q 6 week pembrolizumab dosing schedule FDA approved
Updates on possible PARP inhibitor use.  Niraparib for ovarian maintenance.  Olaparib in prostate cancer (5:28)
The monarcHER study of abemaciclib in HER+ MBC (12:20)
The GRIFFIN study of Dara+VRD in myeloma (17:00)

Updates on possible PARP inhibitor use.  Niraparib for ovarian maintenance.  Olaparib in prostate cancer

The monarcHER study of abemaciclib in HER+ MBC

Capmatinib & SC Daratumumab

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients we cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.